AssetMark Inc
TVTX icon

AssetMark Inc’s Travere Therapeutics TVTX Stock Holding History

AssetMark Inc’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.12M Buy
19,780
+144
+0.7% +$6.38K ﹤0.01% 1068
2026
Q1 		$583K Sell
19,636
-1,931
-9% -$57.7K ﹤0.01% 1136
2025
Q4 		$824K Buy
+21,567
New +$701K ﹤0.01% 1058

Other funds holding TVTX

SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
CFM
Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Calamos Advisors
Calamos Advisors Naperville, Illinois $30.1B AUM 30.03% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return

AssetMark Inc's TVTX Position: Q2 2026 in Review

AssetMark Inc increased its Travere Therapeutics (TVTX) stake by 0.73% in Q2 2026, buying an estimated $6.38K and bringing the position to 19,780 shares worth $1.12M. The position accounts for ﹤0.01% of the portfolio, ranked #1068.

AssetMark Inc first reported a position in TVTX in Q4 2025 and has held it in 3 quarters since. 55 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • AssetMark Inc held 19,780 shares of Travere Therapeutics worth $1.12M as of Q2 2026.
  • AssetMark Inc bought 144 Travere Therapeutics shares in Q2 2026, an estimated $6.38K.
  • Travere Therapeutics made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #1068 holding.
  • AssetMark Inc first reported a position in Travere Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 55 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.